Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149486 · ClinicalTrials.gov registry record · Phase 1
Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01149486: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01149486 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01149486, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The object of this study was to compare the relative bioavailability (rate and extent of absorption) of 100/25 mg Losartan potassium/Hydrochlorothiazide Tablets manufactured by Teva Pharmaceutical Industries Ltd. and distributed by Teva Pharmaceuticals USA with that of Hyzaar® 100/25 mg Tablets distributed by Merck \& Co., Inc. following a single oral dose (1 x 100/25 mg tablet) in healthy adult subjects administered under fasting conditions.
Interventions
- DRUG Losartan potassium/Hydrochlorothiazide
- DRUG Hyzaar®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01149486
The ClinicalTrials.gov registry entry for NCT01149486 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Losartan potassium/Hydrochlorothiazide is the first listed.
NCT01149486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01149486 about?
NCT01149486 is a clinical study titled "Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions". The object of this study was to compare the relative bioavailability (rate and extent of absorption) of 100/25 mg Losartan potassium/Hydrochlorothiazide Tablets manufactured by Teva Pharmaceutical Industries Ltd. and distributed by Teva Pharmaceuticals USA with that of Hyzaar® 100/25 mg Tablets dist...
What is the current status of trial NCT01149486?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2004-01. Estimated completion is 2004-02.
What interventions are being tested in trial NCT01149486?
The interventions under investigation include: Losartan potassium/Hydrochlorothiazide (DRUG), Hyzaar® (DRUG).
Who is sponsoring clinical trial NCT01149486?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.